

guselkumab (Tremfya™)**Policy # 00588**

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Plaque Psoriasis

Based on review of available data, the Company may consider guselkumab (Tremfya™)† for the treatment of adult patients with plaque psoriasis to be **eligible for coverage**.**

Patient Selection Criteria

Coverage eligibility for guselkumab (Tremfya) will be considered when the following criteria are met:

Initial

- Patient has a diagnosis of moderate to severe plaque psoriasis; AND
- Patient is 6 years of age or older; AND
- Patient weighs at least 40 kg; AND
- Patient has a negative tuberculosis (TB) test (e.g., purified protein derivative [PPD], blood test) prior to treatment; AND
- Patient is a candidate for phototherapy or systemic therapy; AND
- Tremfya is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as adalimumab (Humira®, biosimilars)† or etanercept (Enbrel®)† OR other drugs such as tofacitinib (Xeljanz/XR®)† or apremilast (Otezla®/XR)†; AND
- Patient has greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia); AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has failed to respond to an adequate trial of one of the following treatment modalities:
 - Ultraviolet B; OR
 - Psoralen positive Ultraviolet A; OR
 - Systemic therapy (e.g., methotrexate, cyclosporine, acitretin).*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

guselkumab (Tremfya™)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

Continuation

- Patient has received an initial authorization; AND
- Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms.

*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

Psoriatic Arthritis

Based on review of available data, the Company may consider guselkumab (Tremfya) for the treatment of adult patients with active psoriatic arthritis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for guselkumab (Tremfya) will be considered when ALL of the following criteria are met:

Initial

- Patient has a diagnosis of active psoriatic arthritis; AND
- Patient is 6 years of age or older; AND
- Patient weighs at least 40 kg; AND
- Patient has a negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- Tremfya is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as adalimumab (Humira, biosimilars) or etanercept (Enbrel) OR other drugs such as Otezla/XR or Xeljanz/XR; AND
- Patient has failed treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs).

*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

Continuation

- Patient has received an initial authorization; AND
- Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms.

*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

Ulcerative Colitis

Based on review of available data, the Company may consider guselkumab (Tremfya) for the treatment of moderately to severely active ulcerative colitis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for guselkumab (Tremfya) will be considered when ALL of the following criteria are met:

Initial

- Patient has a diagnosis of moderately to severely active ulcerative colitis; AND
- Patient is 18 years of age or older; AND

guselkumab (Tremfya™)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

- Patient has failed or become intolerant to treatment with traditional immunomodulators (e.g., azathioprine, 6-mercaptopurine) or corticosteroids; AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Tremfya is NOT being used concurrently with other biologic products such as infliximab (Remicade®‡, biosimilars), adalimumab (Humira, biosimilars), or vedolizumab (Entyvio®)‡ for the treatment of moderately to severely active ulcerative colitis; AND
- Patient has negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- For Tremfya intravenous requests only: Dosage is 200 mg at week 0, week 4, and week 8.

Continuation

- Patient has received an initial authorization; AND
- Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

Crohn's Disease

Based on review of available data, the Company may consider guselkumab (Tremfya) for the treatment of moderately to severely active Crohn's disease to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for guselkumab (Tremfya) will be considered when ALL of the following criteria are met:

Initial

- Patient has a diagnosis of moderately to severely active Crohn's disease; AND
- Patient is 18 years of age or older; AND
- Patient has failed or become intolerant to treatment with traditional immunomodulators (e.g., azathioprine, 6-mercaptopurine) or corticosteroids OR the patient has failed or become intolerant to a tumor necrosis factor (TNF) blocker or another biologic for the treatment of Crohn's disease such as infliximab (Remicade, biosimilars), adalimumab (Humira, biosimilars), or vedolizumab (Entyvio); AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Tremfya is NOT being used concurrently with other biologic products such as infliximab (Remicade, biosimilars), adalimumab (Humira, biosimilars), or vedolizumab (Entyvio) for the treatment of moderately to severely active Crohn's disease; AND
- Patient has negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- For Tremfya intravenous requests only: Dosage is 200 mg at week 0, week 4, and week 8.

Continuation

- Patient has received an initial authorization; AND

- Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of guselkumab (Tremfya) when any of the following criteria for their respective disease state listed below (and denoted in the patient selection criteria above) are not met to be **not medically necessary****:

- For plaque psoriasis:
 - Patient has greater than 10% BSA OR less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia)
 - Patient has failed to respond to an adequate trial of one of the following treatment modalities:
 - Ultraviolet B; OR
 - Psoralen positive Ultraviolet A; OR
 - Systemic therapy (e.g., methotrexate, cyclosporine, acitretin)
 - For continuation requests: Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms
- For psoriatic arthritis:
 - Patient has failed treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs)
 - For continuation requests: Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms
- For ulcerative colitis:
 - Patient has failed or become intolerant to treatment with traditional immunomodulators (e.g., azathioprine, 6-mercaptopurine) or corticosteroids
 - For continuation requests: Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms
- For Crohn's disease:
 - Patient has failed or become intolerant to treatment with traditional immunomodulators (e.g., azathioprine, 6-mercaptopurine) or corticosteroids OR the patient has failed or become intolerant to a tumor necrosis factor (TNF) blocker or another biologic for the treatment of Crohn's disease
 - For continuation requests: Patient has experienced a beneficial clinical response from baseline (prior to therapy with Tremfya) as evidenced by improvement in clinical signs and/or symptoms

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of guselkumab (Tremfya) when patient selection criteria are not met (with the exception of those denoted as **not medically necessary****) to be **investigational**.*

Background/Overview

Tremfya is an interleukin-23 (IL-23) blocker indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years of age and older who also weigh at least 40 kg and who are candidates for systemic therapy or phototherapy, for the treatment of patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis, for the treatment of adults with moderately to severely active ulcerative colitis, and for the treatment of adults with moderately to severely active Crohn's disease. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Tremfya inhibits the release of pro-inflammatory cytokines and chemokines. Tremfya is supplied as 100 mg in a single-dose prefilled syringe, single dose prefilled pen, or a single dose patient-controlled injector and as 200 mg in a single-dose prefilled pen, single-dose prefilled syringe, or single-dose vial. Tremfya is dosed at 100 mg at weeks 0 and 4 and every 8 weeks thereafter for plaque psoriasis and psoriatic arthritis. For ulcerative colitis, an induction dose of 200 mg administered by intravenous infusion at week 0, week 4, and week 8, and a maintenance dose of 100 mg administered by subcutaneous injection beginning at week 16 and every 8 weeks thereafter or 200 mg administered by subcutaneous injection at week 12 and every 4 weeks thereafter is recommended. The recommended induction dose for Crohn's disease is 200 mg administered by intravenous infusion at weeks 0, 4, and 8 or 400 mg administered by subcutaneous injection at weeks 0, 4, and 8. The maintenance dose for Crohn's disease is 100 mg administered by subcutaneous injection at week 16 and every 8 weeks thereafter, or 200 mg given by subcutaneous injection at week 12 and every 4 weeks thereafter. For ulcerative colitis and Crohn's disease maintenance dosing, the lowest effective recommended dosage should be used to maintain therapeutic response.

Plaque Psoriasis

Psoriasis is a common skin condition that is caused by an increase in production of skin cells. It is characterized by frequent episodes of redness, itching and thick, dry silvery scales on the skin. It is most commonly seen on the trunk, elbows, knees, scalp, skin folds and fingernails. This condition can appear suddenly or gradually and may affect people of any age; it most commonly begins between the ages of 15 and 35. Psoriasis is not contagious. It is an inherited disorder related to an inflammatory response in which the immune system produces too much tumor necrosis factor-alpha (TNF-alpha). It may be severe in immunosuppressed people or those who have other autoimmune disorders such as rheumatoid arthritis. Treatment is focused on control of the symptoms and prevention of secondary infections. Lesions that cover all or most of the body may be acutely painful and require hospitalization. The body loses vast quantities of fluid and becomes susceptible to severe secondary infections that can involve internal organs and even progress to septic shock. Typical treatments for severe cases of plaque psoriasis include ultraviolet therapy or systemic therapies such as methotrexate or cyclosporine. Newer biologic therapies are also approved for the treatment of plaque psoriasis.

guselkumab (Tremfya™)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

Psoriatic Arthritis

Psoriatic arthritis is an arthritis that is often associated with psoriasis of the skin. Typically, first line treatments such as DMARDs (disease modifying anti-rheumatic drugs) are used to treat this condition. An example of a DMARD would include methotrexate.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Disease-modifying anti-rheumatic drugs are typically used for the treatment of inflammatory conditions. These drugs slow the disease process by modifying the immune system.

- methotrexate
- cyclosporine
- sulfasalazine
- mercaptopurine
- gold compounds

Ulcerative Colitis

Ulcerative colitis is a chronic, episodic, inflammatory disease of the large intestine and rectum characterized by bloody diarrhea. This disease usually begins in the rectal area and may eventually extend through the entire large intestine. Repeated episodes of inflammation lead to thickening of the wall of the intestine and rectum with scar tissue. Death of colon tissue or sepsis may occur with severe disease. The goals of treatment are to control the acute attacks, prevent recurrent attacks and promote healing of the colon. Hospitalization is often required for severe attacks. Typically, first line treatments such as corticosteroids, 6-mercaptopurine and azathioprine are used to treat this condition.

Crohn's Disease

Crohn's disease is a chronic autoimmune disease that can affect any part of the gastrointestinal tract but most commonly occurs in the ileum. As a result of the immune attack, the intestinal wall becomes thick, and deep ulcers may form. In addition to the bowel abnormalities, Crohn's disease can also affect other organs in the body. Typically, first line treatments such as corticosteroids, 6-MP and azathioprine are used to treat this condition.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Tremfya is an interleukin-23 blocker approved in July of 2017 for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. In July of 2020, Tremfya was approved for the treatment of adult patients with active psoriatic arthritis. Tremfya gained approval for the treatment of adult patients with moderately to severely active ulcerative colitis in September of 2024. In March of 2025, Tremfya was approved for the treatment of adult patients with moderately to severely active Crohn's disease. In September of 2025, Tremfya's labeled indications for plaque psoriasis and psoriatic arthritis were expanded to include pediatric patients 6 years of age or older weighing at least 40 kg.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Plaque Psoriasis

The safety and efficacy of Tremfya was assessed in two trials. In these trials, subjects were randomized to either Tremfya (100 mg at weeks 0 and 4, then every 8 weeks) or Humira (80 mg at week 0 and 40 mg at week 1, followed by 40 mg every other week thereafter). These two trials assessed the responses at week 16 compared to placebo for the PASI 90 [proportion of subjects who achieved at least a 90% reduction from baseline in the PASI (Psoriasis Area and Severity Index) composite score]. Comparisons between Tremfya and Humira were made via secondary endpoints at weeks 16 and 24. The PASI 90 response in trial 1 was 73% for the Tremfya group vs. 3% in the placebo group. In trial 2, the PASI 90 response was 70% in the Tremfya group vs. 2% in the placebo group. In regards to secondary endpoints vs. Humira, the Tremfya group had higher PASI 75 and PASI 90 responses at various timepoints.

The safety and efficacy of Tremfya in pediatric subjects with moderate-to-severe plaque psoriasis were assessed in one randomized, placebo- and active comparator-controlled trial. In this trial, subjects 6 years to 17 years of age were randomized to receive Tremfya, placebo, or an active biological comparator. Subjects received Tremfya at weeks 0, 4, and 12, with dosing based on body weight. The trial assessed responses at week 16 compared to placebo for two co-primary endpoints: the proportion of subjects who achieved an Investigator's Global Assessment (IGA) score of 0 (cleared) or 1 (minimal) and the proportion of subjects who achieved a PASI 90 response. At week 16, 66% of subjects in the Tremfya group achieved an IGA response of 0 or 1 compared to 16% in the placebo group. The PASI 90 response was 56% in the Tremfya group compared to 16% in the placebo group. Additional outcomes evaluated included PASI 75, PASI 100, and IGA score of 0 at week 16, with higher response rates observed in the Tremfya group compared to placebo.

Psoriatic Arthritis

The safety and efficacy of Tremfya were assessed in two randomized, double-blind, placebo-controlled trials (PsA1 and PsA2) in adult subjects with active psoriatic arthritis who had an inadequate response to standard therapies (e.g., conventional DMARDs, Otezla, or nonsteroidal anti-inflammatory drugs [NSAIDs]). PsA1 evaluated subjects who were treated with placebo, Tremfya 100 mg at weeks 0, 4 and every 8 weeks thereafter, or Tremfya 100 mg every 4 weeks. PsA2 evaluated subjects who were treated with placebo, Tremfya 100 mg at weeks 0, 4 and every 8 weeks thereafter, or Tremfya 100 mg every 4 weeks. The primary endpoint in both trials was the percentage of subjects achieving an ACR20 (20% improvement from baseline in the American College of Rheumatology score) response at week 24. In both trials, subjects treated with Tremfya 100 mg every 8 weeks demonstrated a greater clinical response including ACR20, compared to placebo at week 24. In PsA1, 52% of subjects using Tremfya every 8 weeks achieved an ACR20 versus 22% in the placebo group at week 24. In PsA2, 64% of subjects using Tremfya every 8 weeks achieved an ACR20 versus 33% in the placebo group at week 24.

guselkumab (TremfyaTM)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

Ulcerative Colitis

The safety and efficacy of Tremfya were assessed in 2 studies, an induction and maintenance study. In the induction trial, UC1, subjects with moderately to severely active ulcerative colitis were randomized 3:2 to receive either Tremfya 200 mg or placebo by intravenous infusion at week 0, week 4, and week 8. The primary endpoint was clinical remission at week 12 defined by the modified Mayo Score (mMS). The mMS is a 3-component Mayo score (0-9) which consists of the following subscores (0 to 3 for each subscore): stool frequency (SFS), rectal bleeding (RBS), and findings on centrally reviewed endoscopy (ES). An ES of 2 was defined by marked erythema, lack of vascular pattern, friability, and/or erosions; an ES of 3 was defined by spontaneous bleeding and ulceration. The primary endpoint in UC1 was achieved by 23% of patients in the Tremfya treatment group compared to 8% of patients in the placebo treatment group. In the maintenance trial, UC2, subjects who demonstrated a clinical response to Tremfya IV induction dosing were re-randomized to receive a subcutaneous maintenance regimen of either Tremfya 100 mg every 8 weeks, Tremfya 200 mg every 4 weeks, or placebo for up to an additional 44 weeks. The primary endpoint for UC2 was clinical remission at week 44 defined by mMS. Secondary endpoints included corticosteroid-free clinical remission, endoscopic improvement, histologic endoscopic mucosal improvement, all at week 44 and maintenance of clinical remission at week 44 in subjects who achieved clinical remission 12 weeks after intravenous Tremfya induction treatment. In UC2, 45% of patients receiving Tremfya 100 mg every 8 weeks, 50% of patients receiving Tremfya 200 mg every 4 weeks, and 19% of patients receiving placebo all met the primary endpoint of clinical remission at week 44.

Crohn's Disease

The efficacy and safety of Tremfya were assessed in three randomized, double-blind, placebo-controlled trials that enrolled adult subjects with moderately to severely active Crohn's disease who had a history of inadequate response, loss of response, or intolerance to oral corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), and/or biologic therapy (TNF blockers or vedolizumab). Moderately to severely active Crohn's disease was defined as a Crohn's Disease Activity Index (CDAI) score of ≥ 220 and a Simple Endoscopic Score for Crohn's Disease (SES-CD) of ≥ 6 (or ≥ 4 for subjects with isolated ileal disease). In CD1 and CD2, subjects were randomized to receive intravenous Tremfya 200 mg at weeks 0, 4, and 8 or placebo. The co-primary endpoints were clinical remission at week 12, defined as CDAI score < 150 , and endoscopic response, defined as $> 50\%$ improvement from baseline in SES-CD score. In CD1 and CD2, 47% of subjects receiving Tremfya achieved clinical remission compared to 20% and 15%, respectively, of those receiving placebo. 36% of subjects receiving Tremfya in CD1 and 34% of subjects receiving Tremfya in CD2 had an endoscopic response compared to 9% of subjects receiving placebo in CD1 and 13% of subjects receiving placebo in CD2. In CD3, subjects were randomized to receive subcutaneous Tremfya 400 mg at weeks 0, 4, and 8 followed by subcutaneous Tremfya 100 mg every 8 weeks, subcutaneous Tremfya 400 mg at weeks 0, 4, and 8 followed by subcutaneous Tremfya 200 mg every 4 weeks, or placebo. In CD3, the coprimary endpoints were clinical remission at week 12 and endoscopic response at week 12 compared to placebo. In CD3, 56% of subjects receiving Tremfya achieved clinical remission compared to 22% of subjects receiving placebo. In CD3, 34% of subjects receiving Tremfya had an endoscopic response compared to 15% of those receiving placebo.

guselkumab (Tremfya™)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

References

1. Tremfya [package insert]. Janssen Biotech, Inc. Horsham, Pennsylvania. Updated September 2025.

Policy History

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

12/07/2017	Medical Policy Committee review
12/20/2017	Medical Policy Implementation Committee approval. New policy.
04/05/2018	Medical Policy Committee review
04/18/2018	Medical Policy Implementation Committee approval. Changed prerequisite from TWO products to Humira only for plaque psoriasis.
04/04/2019	Medical Policy Committee review
04/24/2019	Medical Policy Implementation Committee approval. No change to coverage.
07/03/2019	Medical Policy Committee review
07/18/2019	Medical Policy Implementation Committee approval. Removed the requirement for Humira in plaque psoriasis.
07/02/2020	Medical Policy Committee review
07/08/2020	Medical Policy Implementation Committee approval. No change to coverage.
11/05/2020	Medical Policy Committee review
11/11/2020	Medical Policy Implementation Committee approval. Added a new FDA approved indication, psoriatic arthritis. Updated relevant background information.
11/04/2021	Medical Policy Committee review
11/10/2021	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2022	Medical Policy Committee review
11/09/2022	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/02/2023	Medical Policy Committee review
11/08/2023	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/07/2024	Medical Policy Committee review
11/13/2024	Medical Policy Implementation Committee approval. Added new FDA approved indication, ulcerative colitis, with criteria. Updated relevant background information.
06/05/2025	Medical Policy Committee review
06/11/2025	Medical Policy Implementation Committee approval. Added new FDA approved indication, Crohn's disease, with criteria. Added continuation criteria for each indication. Updated relevant background information.
04/02/2026	Medical Policy Committee review
04/10/2026	Medical Policy Implementation Committee approval. Updated coverage eligibility criteria for plaque psoriasis and psoriatic arthritis to align with the FDA-approved label, lowering the minimum age requirement from 18 years to 6 years of age and adding a minimum weight requirement of 40 kg. Updated relevant sections.

Next Scheduled Review Date: 04/2027

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	No code
HCPCS	J1628
ICD-10 Diagnosis	All Related Diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);

guselkumab (Tremfya™)

Policy # 00588

Original Effective Date: 01/01/2018

Current Effective Date: 05/01/2026

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.